Literature DB >> 25477279

NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.

Chao Qu1, Sheri L Bonar1, Cynthia L Hickman-Brecks1, Samer Abu-Amer1, Matthew D McGeough1, Carla A Peña1, Lori Broderick1, Chang Yang1, Susan K Grimston1, Jacqueline Kading1, Yousef Abu-Amer1, Deborah V Novack1, Hal M Hoffman1, Roberto Civitelli1, Gabriel Mbalaviele2.   

Abstract

Activating-mutations in NOD-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) cause neonatal-onset multisystem inflammatory disease. However, the ontogeny of skeletal anomalies in this disorder is poorly understood. Mice globally expressing the D301N mutation in Nlrp3 (D303N in human) model the human phenotype, including systemic inflammation and skeletal deformities. To gain insights into the skeletal manifestations, we generated mice in which the expression of D301N Nlrp3 (Nlrp3( D301N)) is restricted to myeloid cells. These mice exhibit systemic inflammation and severe osteopenia (∼ 60% lower bone mass) similar to mice globally expressing the knock-in mutation, consistent with the paradigm of innate immune-driven cryopyrinopathies. Because systemic inflammation may indirectly affect bone homeostasis, we engineered mice in which Nlrp3( D301N) is expressed specifically in osteoclasts, the cells that resorb bone. These mice also develop ∼ 50% lower bone mass due to increased osteolysis, but there is no systemic inflammation and no change in osteoclast number. Mechanistically, aside from its role in IL-1β maturation, Nlrp3( D301N) expression enhances osteoclast bone resorbing ability through reorganization of actin cytoskeleton while promoting the degradation of poly(ADP-ribose) polymerase 1, an inhibitor of osteoclastogenesis. Thus, NLRP3 inflammasome activation is not restricted to the production of proinflammatory mediators but also leads to cytokine-autonomous responses. © FASEB.

Entities:  

Keywords:  IL-1β; NOMID; PARP1; cryopyrinopathies; osteoclasts

Mesh:

Substances:

Year:  2014        PMID: 25477279      PMCID: PMC4396608          DOI: 10.1096/fj.14-264804

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  29 in total

1.  Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction.

Authors:  Chong-Shan Shi; Kevin Shenderov; Ning-Na Huang; Juraj Kabat; Mones Abu-Asab; Katherine A Fitzgerald; Alan Sher; John H Kehrl
Journal:  Nat Immunol       Date:  2012-01-29       Impact factor: 25.606

Review 2.  ADP-ribosylation of histones by ARTD1: an additional module of the histone code?

Authors:  Michael O Hottiger
Journal:  FEBS Lett       Date:  2011-03-21       Impact factor: 4.124

Review 3.  Genetic and molecular basis of inflammasome-mediated disease.

Authors:  Hal M Hoffman; Susannah D Brydges
Journal:  J Biol Chem       Date:  2011-02-04       Impact factor: 5.157

4.  Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.

Authors:  Noam Levaot; Oleksandr Voytyuk; Ioannis Dimitriou; Fabrice Sircoulomb; Arun Chandrakumar; Marcel Deckert; Paul M Krzyzanowski; Andrew Scotter; Shengqing Gu; Salima Janmohamed; Feng Cong; Paul D Simoncic; Yasuyoshi Ueki; Jose La Rose; Robert Rottapel
Journal:  Cell       Date:  2011-12-09       Impact factor: 41.582

5.  RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.

Authors:  Jianfeng Chen; Yong Sun; Xia Mao; Qizhan Liu; Hui Wu; Yabing Chen
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

6.  Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes.

Authors:  Süheda Erener; Virginie Pétrilli; Ingrid Kassner; Roberta Minotti; Rosa Castillo; Raffaella Santoro; Paul O Hassa; Jürg Tschopp; Michael O Hottiger
Journal:  Mol Cell       Date:  2012-03-29       Impact factor: 17.970

7.  Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA).

Authors:  Donato Rigante; Antonio Leone; Raffaella Marrocco; Maria Elena Laino; Achille Stabile
Journal:  Rheumatol Int       Date:  2011-01-15       Impact factor: 2.631

8.  Cutting edge: proteolytic inactivation of poly(ADP-ribose) polymerase 1 by the Nlrp3 and Nlrc4 inflammasomes.

Authors:  R K Subbarao Malireddi; Sirish Ippagunta; Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  J Immunol       Date:  2010-08-16       Impact factor: 5.422

9.  The inflammasome adaptor ASC regulates the function of adaptive immune cells by controlling Dock2-mediated Rac activation and actin polymerization.

Authors:  Sirish K Ippagunta; R K Subbarao Malireddi; Patrick J Shaw; Geoffrey A Neale; Lieselotte Vande Walle; Douglas R Green; Yoshinori Fukui; Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2011-09-04       Impact factor: 25.606

10.  Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice.

Authors:  Sheri L Bonar; Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla Pena; Debbie Chen; Susan K Grimston; Cynthia L Hickman-Brecks; Soumya Ravindran; Audrey McAlinden; Deborah V Novack; Daniel L Kastner; Roberto Civitelli; Hal M Hoffman; Gabriel Mbalaviele
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more
  32 in total

Review 1.  Inflammasomes in the pathophysiology of autoinflammatory syndromes.

Authors:  Sarang Tartey; Thirumala-Devi Kanneganti
Journal:  J Leukoc Biol       Date:  2019-10-14       Impact factor: 4.962

Review 2.  Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity.

Authors:  Matthew C Walsh; Noriko Takegahara; Hyunsoo Kim; Yongwon Choi
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

3.  NLRP3 inflammasome activation triggers gasdermin D-independent inflammation.

Authors:  Chun Wang; Tong Yang; Jianqiu Xiao; Canxin Xu; Yael Alippe; Kai Sun; Thirumala-Devi Kanneganti; Joseph B Monahan; Yousef Abu-Amer; Judy Lieberman; Gabriel Mbalaviele
Journal:  Sci Immunol       Date:  2021-10-22

Review 4.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

Review 5.  Osteoclasts-Key Players in Skeletal Health and Disease.

Authors:  Deborah Veis Novack; Gabriel Mbalaviele
Journal:  Microbiol Spectr       Date:  2016-06

6.  Osteoimmunology: entwined regulation of integrated systems.

Authors:  Mary C Nakamura
Journal:  Semin Immunopathol       Date:  2019-09       Impact factor: 9.623

7.  Site-1 protease controls osteoclastogenesis by mediating LC3 transcription.

Authors:  Zeyu Zheng; Xuyang Zhang; Bao Huang; Junhui Liu; Xiaoan Wei; Zhi Shan; Hao Wu; Zhenhua Feng; Yilei Chen; Shunwu Fan; Fengdong Zhao; Jian Chen
Journal:  Cell Death Differ       Date:  2021-01-19       Impact factor: 12.067

8.  [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].

Authors:  Haiyan Yan; Chuncai Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

9.  PARP1 Hinders Histone H2B Occupancy at the NFATc1 Promoter to Restrain Osteoclast Differentiation.

Authors:  Chun Wang; Jianqiu Xiao; Kathrin Nowak; Kapila Gunasekera; Yael Alippe; Sheree Speckman; Tong Yang; Dustin Kress; Yousef Abu-Amer; Michael O Hottiger; Gabriel Mbalaviele
Journal:  J Bone Miner Res       Date:  2020-01-07       Impact factor: 6.741

Review 10.  Inflammasomes in Alveolar Bone Loss.

Authors:  Yang Li; Junqi Ling; Qianzhou Jiang
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.